Thursday, 13 March 2025
  
Login

Australia's most trusted
source of pharma news

Thursday, 13 March 2025
Ascott/Nuevo
Ascott/Nuevo
Latest News
Roche bets on obesity trump card

Roche has shored up its obesity portfolio by partnering with Zealand Pharma for a much-hyped amylin analog in Phase 2 trials in a deal worth up to AU$8.3 billion.

Astellas carves niche for Xtandi
Beats Bayer and J&J to new cancer indication as generic versions of its top earning drug in Australia circle
TODAY
AZ laser-focused on 1M target
Business Unit Director for Cardiovascular Renal and Metabolism, Cecelia Bagley, exposes the urgent need for policy reform in Australia
TODAY
Most Popular
Where HCPs are feeling fresh pain
These doctors have a brand new top pain point, opening an opportunity for pharma to help ease the burden
12 March
Drug racing to $1 billion on PBS
With a super start to 2025, could this drug crack ten digits by year's end?
11 March
40-year-old pharma rebrands
Company returns to Australian ownership with a new name and an ex-Pharmac boss to drive growth as the new CEO
11 March
Amid job cuts, boss trims pay
With a major company restructure underway, this CEO is also feeling the pinch with a 20 per cent drop in compensation year-on-year
11 March
Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (1)

Sales & Customer Relations (37)

Clinical & Medical, R&D (15)

Regulatory, Pharmacovigilance & QA (1)

Executive Roles (1)

Other (20)

More News
Senior leader lands former job
After leaving Australia and a top Corporate Affairs job, this executive is back with her former company in her previous role
TODAY
High Court refuses Bayer's appeal
Fight to protect patents for a blockbuster is done and dusted, with the final legal avenue closed
TODAY
Drug safety alert extended to men
Sponsor of originator product adds new warnings as a precaution with generic drug makers following suit
12 March
Gilead leapfrogs to Phase 3 trial
A Phase 1 trial of an annual injection was so successful that the pharma is skipping Phase 2
12 March
Multi-billion dollar hopeful falters
J&J discontinues program for much-anticipated drug which had been expected to bring in US$5 billion-a-year
12 March
Trump risks $2B in Aussie meds
US trade war would impact billions in local medicinal and pharmaceutical exports if tariffs are implemented
12 March
HCPs flock to genetic experts
Virtual boards funded by AstraZeneca and Roche are proving a hit with HCPs looking for expert advice on complex cancer cases
11 March
Opportunity knocks for BeiGene
'Once-in-a-lifetime opportunity' arrives as Brukinsa success sees pharma enter profitability
11 March
Two pharmas clinch supplier gongs
Pharmacy network celebrates suppliers making exceptional efforts in supporting healthcare products
10 March
Aussies spearhead care revolution
Embedding research into clinical care brings forward the time patients can benefit from scientific advances
10 March
Which Aussie pharma pays most?
Compulsory WGEA reporting has revealed the average pay at large pharmas in Australia
10 March
Sanofi snags new vaccines leader
Professorial fellow appointed to lead the company's vaccines business in Australia, New Zealand and South Korea
10 March
Three brands hit with first generic
GLP-1 receptor agonist copycat among three brands hit with the first generic on the ARTG last week
10 March Approvals Action
Company gifts a long weekend
Which company has given the entire team the day off in honour of International Women's Day?
7 March
PiF advertise
PiF advertise
© 2003 - 2025 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home
Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe